Inactive Instrument

News Cytori Therapeutics Inc Nasdaq

Equities

US23283K2042

Summary

Unlock all the news: Be the first to know and act before the market!

Plus Therapeutics to Present at the Gordon Research Conference Radionuclide Theranostics for the Management of Cancer	Jul. 02	AQ
Rhenium (186Re) Obisbemeda (186RNL) in Leptomeningeal Metastases Phase 1 Dose Escalation Trial: Update for Initial Safety, Feasibility and Preliminary Efficacy	Jun. 11	PU
Plus Therapeutics, Inc. Receives the Resignation of Dr. Norman Lafrance, Its Chief Medical Officer, Effective June 12, 2024	Jun. 07	CI
Plus Therapeutics to Receive $3.3 Million Advance Payment From CPRIT For Radiotherapeutic Development Program	Jun. 07	MT
Plus Therapeutics Expands Management Team and Reports $3.3M Advance Payment from CPRIT	Jun. 07	AQ
Plus Therapeutics, Inc. Draws $3.3 Million on Its Existing Margin Loan Facility with Pershing Llc	Jun. 04	CI
Plus Therapeutics Announces New Employment Inducement Grants	May. 17	AQ
Transcript : Plus Therapeutics, Inc., Q1 2024 Earnings Call, May 15, 2024	May. 15
Plus: Q1 Earnings Snapshot	May. 15	AQ
Plus Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights	May. 15	AQ
Plus Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 15	CI
Plus Therapeutics to Announce First Quarter Financial Results and Host Conference Call on May 15, 2024	May. 13	AQ
Plus Therapeutics : Material Agreement - Form 8-K	May. 09	PU
Plus Therapeutics Provides Highlights Regarding Leptomeningeal Metastases Acquisition and Topline Clinical Trial Data on the FORESEE Trial	May. 09	AQ
Transcript : Plus Therapeutics, Inc. - Special Call	May. 09
Plus Therapeutics, Inc. acquired CNSide, a leptomeningeal metastases diagnostic platform.	May. 08	CI
Plus Therapeutics, Inc. announced that it has received $7.262078 million in funding from Aigh Capital Management, LLC	May. 08	CI
Plus Therapeutics to Host Investor Call to Discuss Leptomeningeal Cancer Related Acquisition and Topline Clinical Trial Data from the FORESEE Trial	May. 08	AQ
Plus Therapeutics : The use of CNSide in Clinical Management of LMD	May. 08	PU
Plus Therapeutics Announces Private Placement Financing of up to $18 Million	May. 06	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Cytori Therapeutics Inc Nasdaq

Equities

US23283K2042

Summary

Filters